Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.850
-0.090 (-4.64%)
At close: Apr 2, 2026, 4:00 PM EDT
1.950
+0.100 (5.41%)
After-hours: Apr 2, 2026, 7:56 PM EDT
Gain Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
25
Market Cap
78.15M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 55.18K | -84.93K | -60.62% |
| Dec 31, 2022 | 140.11K | -24.89K | -15.08% |
| Dec 31, 2021 | 164.99K | 136.11K | 471.29% |
| Dec 31, 2020 | 28.88K | -12.42K | -30.07% |
| Dec 31, 2019 | 41.30K | 20.69K | 100.40% |
| Dec 31, 2018 | 20.61K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 63.26M |
| Champions Oncology | 57.95M |
| NeurAxis | 3.57M |
| Coeptis Therapeutics Holdings | 1.36M |
| aTyr Pharma | 190.00K |
| Inovio Pharmaceuticals | 65.34K |
| eXoZymes | -700.00 |
GANX News
- 8 days ago - Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update - GlobeNewsWire
- 14 days ago - Gain Therapeutics to Present at the 38th Annual ROTH Conference - GlobeNewsWire
- 15 days ago - Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 - GlobeNewsWire
- 22 days ago - Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update - GlobeNewsWire
- 6 weeks ago - Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 3 months ago - Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week - GlobeNewsWire
- 3 months ago - Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 - GlobeNewsWire
- 3 months ago - Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease - GlobeNewsWire